Alendronate sodium
Names
[ CAS No. ]:
121268-17-5
[ Name ]:
Alendronate sodium
[Synonym ]:
Alendronate sodium
(4-Amino-1-hydroxy-1-phosphonobutyl)phosphonic Acid Monosodium Salt Trihydrate
4-amino-1-hydroxy-1-phosphonobutyl phosphonic acid,monosodium,Alendronate sodium trihydrate
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-, sodium salt, hydrate (1:1:3)
Alendronate sodium trihydrate
Sodium Alendronate Trihydrate
hydrogène (4-amino-1-hydroxy-1-phosphonobutyl)phosphonate de sodium trihydrate
alendronate sodium hydrate
Monosodium (4-Amino-1-hydroxy-1-phosphonobutyl)phosphonate Trihydrate
Alendronate monosodium trihydrate
MFCD01748233
Alendronic acid monosodium salt trihydrate
Sodium hydrogen (4-amino-1-hydroxy-1-phosphonobutyl)phosphonate hydrate (1:1:3)
onclast
Adronat
Natriumhydrogen-(4-amino-1-hydroxy-1-phosphonobutyl)phosphonattrihydrat
4-amino-1-hydroxy-1-phosphonobutyl phosphonic acid,monosodium MK-217
Dronal
Sodium alendronate
Alendronate (sodium hydrate)
Biological Activity
[Description]:
[Related Catalog]:
[Target]
IC50: 460 nM (farnesyl diphosphate synthase)
[In Vitro]
[In Vivo]
[Kinase Assay]
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.857g/cm3
[ Boiling Point ]:
616.7ºC at 760 mmHg
[ Melting Point ]:
245°C
[ Molecular Formula ]:
C4H18NNaO10P2
[ Molecular Weight ]:
325.124
[ Flash Point ]:
326.7ºC
[ Exact Mass ]:
325.030365
[ PSA ]:
211.45000
[ Storage condition ]:
−20°C
[ Stability ]:
Store in freezer
[ Water Solubility ]:
water, double-distilled: 10 mg/mL
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- SZ6523500
- CHEMICAL NAME :
- Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-, monosodium salt, trihydrate
- CAS REGISTRY NUMBER :
- 121268-17-5
- LAST UPDATED :
- 199609
- DATA ITEMS CITED :
- 9
- MOLECULAR FORMULA :
- C4-H13-N-O7-P2.3H2-O.Na
- MOLECULAR WEIGHT :
- 294.17
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 700 ug/kg/7D-I
- TOXIC EFFECTS :
- Gastrointestinal - changes in structure or function of esophagus Gastrointestinal - other changes
- REFERENCE :
- AJGAAR American Journal of Gastroenterology. (American College of Gastroenterology, Inc., 428 E. Preston St., Baltimore, MD 21202) V.21- 1954- Volume(issue)/page/year: 90,1889,1995
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 30 mg/kg
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Gastrointestinal - ulceration or bleeding from stomach
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3229,1994
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 10 mg/kg
- TOXIC EFFECTS :
- Behavioral - ataxia Gastrointestinal - nausea or vomiting Nutritional and Gross Metabolic - body temperature decrease
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3229,1994 ** OTHER MULTIPLE DOSE TOXICITY DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 9100 ug/kg/13W-I
- TOXIC EFFECTS :
- Blood - pigmented or nucleated red blood cells Blood - changes in erythrocyte (RBC) count Nutritional and Gross Metabolic - weight loss or decreased weight gain
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3244,1994 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 510 mg/kg
- SEX/DURATION :
- female 14 day(s) pre-mating - 20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - parturition Reproductive - Maternal Effects - other effects Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
- REFERENCE :
- TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 121,217,1993
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 42 mg/kg
- SEX/DURATION :
- male 9 week(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - other effects Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - other measures of fertility
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3319,1994
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 27500 ug/kg
- SEX/DURATION :
- female 7-17 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical Reproductive - Effects on Newborn - delayed effects
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3339,1994
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 26 mg/kg
- SEX/DURATION :
- female 17-21 day(s) after conception lactating female 21 day(s) post-birth
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical Reproductive - Effects on Newborn - delayed effects
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3373,1994
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 650 ug/kg
- SEX/DURATION :
- female 6-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - other effects
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3363,1994
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H302
[ Precautionary Statements ]:
P301 + P312 + P330
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves
[ Hazard Codes ]:
Xn,Xi
[ Risk Phrases ]:
R22:Harmful if swallowed. R36/37/38:Irritating to eyes, respiratory system and skin .
[ Safety Phrases ]:
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . S36:Wear suitable protective clothing .
[ RIDADR ]:
NONH for all modes of transport
[ WGK Germany ]:
3
[ RTECS ]:
SZ6523500
[ HS Code ]:
29310095
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Articles
Nat. Commun. 6 , 6218, (2015)
Osteoporosis is caused by excessive activity of bone-degrading osteoclasts over bone-forming osteoblast. Standard antiosteolytic treatments inhibit bone resorption by inducing osteoclast loss, with th...
Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.Urology 81(4) , 731-7, (2013)
To analyze the effects of aminobisphosphonates and thiazides on renal lithogenic activity and bone mineral density in patients with recurring renal calcium lithiasis.A prospective cohort study with 3 ...
Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice.Arthritis. Res. Ther. 17 , 30, (2015)
Previous studies in animal models of osteoarthritis suggest that alendronate (ALN) has antiresorptive and chondroprotective effects, and can reduce osteophyte formation. However, these studies used no...